Of the 235 tumours that were assessed for CDX2 status, the LNM rate was 46 per cent (17 of 37) in CDX2− tumours and 26·3 per cent (52 of 198) in CDX2+ tumours. The gene discussed is CDX2; the disease is neoplasm.